Integrilin

Generic name: Eptifibatide
Drug class: Glycoprotein platelet inhibitors

Usage of Integrilin

Integrilin helps to prevent platelets in your blood from sticking together and forming a blood clot. An unwanted blood clot can occur with certain heart or blood vessel conditions.

Integrilin is used to prevent blood clots or heart attack in people with severe chest pain or other conditions, and in those who are undergoing a procedure called angioplasty (to open blocked arteries).

Integrilin may also be used for purposes not listed in this medication guide.

Integrilin side effects

Get emergency medical help if you have signs of an allergic reaction to Integrilin: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Tell your caregivers right away if you have:

  • a light-headed feeling, like you might pass out;
  • any bleeding that will not stop;
  • bleeding around your IV or catheter, or in any place where your skin has been punctured with a needle;
  • red or pink urine; or
  • signs of stomach bleeding - bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.
  • The risk of bleeding may be higher in older adults.

    Common Integrilin side effects may include:

  • bleeding; or
  • feeling lightheaded.
  • This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Before taking Integrilin

    You should not use Integrilin if you are allergic to eptifibatide, or if you have:

  • kidney failure and you are on dialysis;
  • severe or uncontrolled high blood pressure;
  • a bleeding or blood-clotting disorder, such as hemophilia or thrombocytopenia;
  • if you have had a stroke or any type of bleeding within the past 30 days;
  • if you have had any type of surgery, injury, or medical emergency within the past 6 weeks; or
  • if you have or will soon receive treatment with similar medications such as aBCiximab (ReoPro) or tirofiban (Aggrastat).
  • To make sure you can safely receive Integrilin, tell your doctor if you have kidney disease.

    Integrilin is not expected to be harmful to an unborn baby. However, aspirin is sometimes given with Integrilin, and aspirin can cause bleeding when it is taken during the last 3 months of pregnancy. Aspirin can also cause side effects in a newborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

    It is not known whether eptifibatide passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.

    Relate drugs

    How to use Integrilin

    Integrilin is injected into a vein through an IV. A healthcare provider will give you this medicine. Integrilin is sometimes given around the clock for up to 4 days in a row.

    If you are receiving this injection during an angioplasty procedure, the medicine will be given throughout the entire procedure and for up to 24 hours after the procedure.

    Integrilin is sometimes given together with aspirin. Follow your doctor's instructions about how much aspirin to take and for how long.

    To be sure this medicine is helping your condition and is not causing harmful effects, your blood will need to be tested often.

    Because Integrilin keeps your blood from coagulating (clotting), this medicine can also make it easier for you to bleed, even from a minor injury. Contact your doctor or seek emergency medical attention if you have any bleeding that will not stop.

    Usual Adult Dose for Myocardial Infarction:

    Initial: 180 mcg/kg intravenous bolus administered as soon as possible following diagnosis Maintenance: 2 mcg/kg/min continuous infusion (following the initial bolus) until hospital discharge or initiation of CABG surgery, up to 72 hours. If a patient is to undergo a percutaneous coronary intervention (PCI) while receiving Integrilin, the infusion should be continued up to hospital discharge, or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. In patients who undergo coronary artery bypass graft surgery, Integrilin infusion should be discontinued prior to surgery.

    Usual Adult Dose for Angina Pectoris:

    Initial: 180 mcg/kg intravenous bolus administered as soon as possible following diagnosis Maintenance: 2 mcg/kg/min continuous infusion (following the initial bolus) until hospital discharge or initiation of CABG surgery, up to 72 hours. If a patient is to undergo a percutaneous coronary intervention (PCI) while receiving Integrilin, the infusion should be continued up to hospital discharge, or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. In patients who undergo coronary artery bypass graft surgery, Integrilin infusion should be discontinued prior to surgery.

    Usual Adult Dose for Acute Coronary Syndrome:

    Initial: 180 mcg/kg intravenous bolus administered as soon as possible following diagnosis Maintenance: 2 mcg/kg/min continuous infusion (following the initial bolus) until hospital discharge or initiation of CABG surgery, up to 72 hours. If a patient is to undergo a percutaneous coronary intervention (PCI) while receiving Integrilin, the infusion should be continued up to hospital discharge, or for up to 18 to 24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy. In patients who undergo coronary artery bypass graft surgery, Integrilin infusion should be discontinued prior to surgery.

    Usual Adult Dose for Percutaneous Coronary Intervention:

    Initial: 180 mcg/kg intravenous bolus administered immediately before the initiation of PCI followed by a continuous infusion of 2 mcg/kg/min and a second 180 mcg/kg bolus 10 minutes after the first bolus. Infusion should be continued until hospital discharge, or for up to 18 to 24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended by the manufacturer. Alternatively, an infusion duration of 16 hours may be appropriate as noted in the ESPRIT substudy. In patients who undergo coronary artery bypass graft surgery, Integrilin infusion should be discontinued prior to surgery.

    Warnings

    You should not receive Integrilin if you are also being treated with similar medications such as abciximab (ReoPro) or tirofiban (Aggrastat).

    You should not receive Integrilin if: you have severe or uncontrolled high blood pressure; you are on dialysis due to kidney failure; you have a bleeding or blood-clotting disorder; you had a stroke or any type of bleeding within the past 30 days; or you had any type of surgery, injury, or medical emergency within the past 6 weeks.

    Tell your doctor if you are pregnant or plan to become pregnant during treatment with Integrilin and aspirin.

    Because Integrilin keeps your blood from coagulating (clotting) to prevent unwanted blood clots, it can also make it easier for you to bleed, even from a minor injury. Contact your doctor or seek emergency medical attention if you have bleeding that will not stop.

    What other drugs will affect Integrilin

    Tell your doctor about all your current medicines and any you start or stop using, especially:

  • NSAIDs (nonsteroidal anti-inflammatory drugs) - aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), Celecoxib, diclofenac, indomethacin, meloxicam, and others;
  • a blood thinner - warfarin, Coumadin, Jantoven; or
  • any other medicines to treat or prevent blood clots - Plavix, Pradaxa, Xarelto, Ticlid, and others.
  • This list is not complete. Other drugs may interact with eptifibatide, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords